[Effects of Oral Magnesium and Antacid Administration on Serum Magnesium Levels and Renal Function in Patients Receiving Cisplatin]
Kamo Y, Sato J, Tanaka R, Shino M
Gan to kagaku ryoho. Cancer & chemotherapy · 0 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2020-04-01 · Gan To Kagaku Ryoho · vol. 47 · issue 4 · pp. 605–608
- Publisher
- National Institutes of Health
- Cited
- 0 citations · more than 5% of similar papers · 0.0× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Magnesium in Health and Disease
- Keywords
- Hypomagnesemia, Antacid, Medicine, Renal function, Magnesium, Oral administration, Internal medicine, Cisplatin, Gastroenterology, Pharmacology, Chemotherapy, Chemistry
- MeSH
- humans, cisplatin, magnesium, magnesium oxide, antacids, administration, oral, retrospective studies
4 authors
From JP
- Yoshiko KamoShizuoka Cancer Center
- Junya Sato
- Rei Tanaka
- Michihiro Shino
Abstract
The efficacy of magnesium oxide(MgO)when taken daily as a laxative for hypomagnesemia and renal dysfunction due to cisplatin(CDDP)administration is not clear. It is known that the efficacy of MgO is suppressed when used in combination with antacids, such as proton pump inhibitors. Therefore, we conducted a retrospective analysis of the effects of MgO and antacid administration on serum Mg levels and renal function(estimated glomerular filtration rate: eGFR)in CDDP-treated patients. In the analysis of up to 6 cycles of CDDP administration, the serum Mg levels and eGFR of CDDP-treated patients (n=614)were significantly reduced(p<0.001 and p=0.002, respectively, ANOVA). Patients who used MgO had higher serum Mg levels than patients who did not use MgO(p<0.001, ANOVA). However, no effect of MgO administration was observed on eGFR(p=0.832, ANOVA). There was no effect of antacid combination on serum Mg levels and eGFR in patients receiving MgO. MgO use may have contributed to a reduction in hypomagnesemia. However, it was considered that the decrease in eGFR could not be suppressed as the improvement in hypomagnesemia was slight. Intravenous Mg supplementation is required when CDDP is administered. Furthermore, it is expected that oral Mg supplementation will improve Mg absorption.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.